Paul Hughes has joined the board of directors at Benaroya Research Institute at Virginia Mason (BRI), a medical research institute internationally known for discoveries in autoimmune disease, allergy and asthma. Mr. Hughes is currently the Managing Director of Investment Banking at Blacktorch Capital, LLC in Seattle. He has been a financial consultant for more than 33 years across healthcare, medical device, pharmaceutical, sports and banking organizations. His experience extends from debt/equity transactions, financial restructuring, mergers and acquisitions to recapitalizations, management buyouts and other areas of finance.Benaroya Research Institute at Virginia Mason (BRI) is committed to finding causes and cures for autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis, and immune system diseases such as allergies and asthma. An internationally-recognized medical research institute, BRI accelerates discovery through laboratory breakthroughs in immunology that are then translated to clinical therapies. BRI is a leader of collaborative initiatives through the Immune Tolerance Network, Type 1 Diabetes TrialNet and other major cooperative research programs. Visit BenaroyaResearch.org or follow Benaroya Research Institute on Facebook, LinkedIn, or Twitter to learn more.
Benaroya Research Institute at Virginia Mason
Nonprofit Medical Research
New Title or Honor: